polyangiitis


Also found in: Medical.
Translations

polyangiitis

n poliangeítis f; microscopic — poliangeítis microscópica
Mentioned in ?
References in periodicals archive ?
THE FOOD AND DRUG Administration approved mepolizumab to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA) in December, making it the first therapy approved for treating this rare disease.
Truxima, the first biosimilar cancer drug to hit the European market in February, is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and microscopic polyangiitis.
GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.
M2 EQUITYBITES-December 13, 2017-GSK awarded US FDA approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA)
Granulomatosis with polyangiitis is an autoimmune disease, characterized by involvement of small vessels and presence of anti-cytoplasmic antibodies (ANCA).
plasma cells, (27,34) including granulomatosis with polyangiitis, (35) multicentric Castleman disease, (36) Rosai-Dorfman disease, (37) marginal zone lymphoma, (38-41) pancreatic adenocarcinoma, (42,43) and even reactive lymphadenopathy, (44) to name just a few.
ANCA-associated small-vessel vasculitis includes microscopic polyangiitis, Wegner's granulomatosis, and Churg-Strauss syndrome.
It also reviews key players involved in the therapeutic development for Wegener Polyangiitis and special features on late-stage and discontinued projects.
Primary anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a chronic multisystem autoimmune disease that includes microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA; Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EPGA; Churg-Strauss syndrome), and localized forms of these diseases.
CT-P10 is a proposed mAb biosimilar to Rituxan (rituximab), which is used to treat Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Wegener's Granulomatosis and Microscopic Polyangiitis (MPA).
Symptoms of granulomatosis with polyangiitis may include numbness in limbs, blood in urine, coughing bloody phlegm, skin sores or bruising, fever, fatigue, and shortness of breath.
Granulomatous inflammation can be found in many conditions other than TB like sarcoidosis, fungal infections, histoplasmosis, leprosy, non-tuberculous mycobacteria, actinomycosis and non-infectious conditions like Crohn's disease, polyangiitis with granulomatosis, foreign body and Langerhan cell histiocytosis.